menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Deliver reliable, scalable, and regulatory-ready eCOA for global Central Nervous System (CNS) trials.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Expert guidance for capturing high-quality, regulatory compliant data from the right participants, at the right time, in clinic or at home.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Improve your data quality, monitor for proper technique and leverage the power of AI to make interpretation of spirometry tests easier, faster and more consistent.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG — On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials
        • eCOA Neuroscience
        • eCOA Rapid Start
        • eCOA Science Services
        • eCOA Rater and Participant Training
        • eCOA Rescue Studies
        • Suicidal Ideation
        • eCOA Live
        • eCOA Multimedia
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Respiratory Solutions for Healthcare Providers
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Dementias
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Get started
  1. Home Resources Downloads Impact of Artificial Intelligence over-reading for instant feedback on quality of home spirometry

Impact of Artificial Intelligence over-reading for instant feedback on quality of home spirometry

Rationale: When performing spirometry, the acceptability of FEV1 and FVC are assessed based on the ATS/ERS quality guidelines. High quality of these parameters in clinical trials is important to assess efficacy, guide relevant clinical decisions and safety monitoring. Spirometry in the home setting is being explored as a promising assessment in many clinical trials. The amount of data generated is demanding to manually process in terms of quality assessment. In this study, we are investigating the impact of instant feedback provided by an AI algorithm (ArtiQ.QC) on the quality of home spirometry.  

Methods: Weekly home spirometry data of 70 patients enrolled in an asthma clinical trial, has been prospectively followed between March and September 2022 by the AI algorithm. AI-based software (ArtiQ.QC  v1.3.0, ArtiQ NV, BE) is capable of an instant quality check of both qualitative and quantitative parameters. Each home spirometry session was assessed by the AI algorithm, for both FEV1 and FVC parameters. Acceptability is based on 2005 guidelines1 due to the capability of the home spirometer. For half of the randomly picked subjects, AI-based feedback is provided to the investigators highlighting the points needing improvement. The second half was also AI-assessed, with no feedback provided. Each month, the proportion of FEV1 and FVC acceptability (defined as grade A or B) is assessed and compared between the two groups. A Fisher test is used to check for significant differences (p-value < 5%). 

Results: A general improvement over time in FEV1 and FVC acceptability is observed in both groups, indicating a strong learning effect (Table 1). The acceptability rate of FEV1 is slightly higher than the one of FVC. Improved acceptability for both FEV1 and FVC from the 3rd month onward in the group with instant feedback was observed. Difference between the groups was significant at month 5 (p = 0.003 for FEV1 and 0.002 for FVC). In the last period, the difference between the 2 groups was 12% for FEV1 and 14%for FVC.   

Conclusions: By providing direct feedback on the quality of home spirometry to the investigators using an AI algorithm, the proportion of acceptable curves increases. This indicates that AI can optimize the quality of home spirometry and support investigators in educating patients on spirometry performance.  

Authors: P. Desbordes1, Cuyvers11, E. Topole2, S. Biondaro2, I. Montagna2, S. Corre2, M. Topalovic1

Affiliations:  

1. ArtiQ NV, Leuven, Belgium

2. Global Clinical Development, Chiesi Farmaceutici S.p.A; Parma, Italy 

Download
Back to downloads
Share
Twitter Facebook LinkedIn

Latest Downloads

See all
Datasheet

Centralized FOT Services

Download icon Download icon
Download
White Paper

AI-enabled risk based monitoring – Cardiac Safety

Download icon Download icon
Download
White Paper

AI-enabled risk-based monitoring – Respiratory

Download icon Download icon
Download
Checklist

Top 5 questions biotech companies should ask to enable study success

Read icon Read icon
Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Get started

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.

Step 1 of 2 - Quick and easy to complete

Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2026 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum